Growth Metrics

Ensysce Biosciences (ENSC) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Ensysce Biosciences' Income from Continuing Operations fell 68491.7% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 3939.96%. This contributed to the annual value of -$8.0 million for FY2024, which is 2756.07% up from last year.
  • Per Ensysce Biosciences' latest filing, its Income from Continuing Operations stood at -$3.7 million for Q3 2025, which was down 68491.7% from -$1.8 million recorded in Q2 2025.
  • Ensysce Biosciences' Income from Continuing Operations' 5-year high stood at $640683.0 during Q3 2024, with a 5-year trough of -$16.9 million in Q3 2021.
  • In the last 5 years, Ensysce Biosciences' Income from Continuing Operations had a median value of -$2.7 million in 2023 and averaged -$3.8 million.
  • In the last 5 years, Ensysce Biosciences' Income from Continuing Operations plummeted by 262352.48% in 2021 and then skyrocketed by 12359.82% in 2024.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Income from Continuing Operations stood at -$2.0 million in 2021, then plummeted by 209.65% to -$6.3 million in 2022, then surged by 44.02% to -$3.5 million in 2023, then fell by 2.48% to -$3.6 million in 2024, then fell by 4.47% to -$3.7 million in 2025.
  • Its Income from Continuing Operations stands at -$3.7 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.0 million for Q1 2025.